Attention deficit-hyperactivity disorder may be a risk factor for treatment-emergent tardive dyskinesia induced by risperidone [9]

Journal of Clinical Psychopharmacology

Volumn 20, Issue 1, 2000, Pages 112-113

  Silver, Henry ^a   Aharon, Nelson ^a   Schwartz, Miguel ^b  

^a Flugelman Mazra Psychiatric Hospital   (Israel)

^b BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PROLACTIN; RISPERIDONE;

ADULT; ATTENTION DEFICIT DISORDER; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; LETTER; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; PROLACTIN; PSYCHOTIC DISORDERS; RISPERIDONE;

EID: 0033983318     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200002000-00025     Document Type: Letter

References (23)